AU2013249495B2 - Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain - Google Patents

Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain Download PDF

Info

Publication number
AU2013249495B2
AU2013249495B2 AU2013249495A AU2013249495A AU2013249495B2 AU 2013249495 B2 AU2013249495 B2 AU 2013249495B2 AU 2013249495 A AU2013249495 A AU 2013249495A AU 2013249495 A AU2013249495 A AU 2013249495A AU 2013249495 B2 AU2013249495 B2 AU 2013249495B2
Authority
AU
Australia
Prior art keywords
insulin
formulation
magnesium
edta
biod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013249495A
Other languages
English (en)
Other versions
AU2013249495A1 (en
Inventor
Robert Hauser
Ming Li
Roderike Pohl
Bryan R. Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2013249495A1 publication Critical patent/AU2013249495A1/en
Application granted granted Critical
Publication of AU2013249495B2 publication Critical patent/AU2013249495B2/en
Assigned to ELI LILLY AND COMPANY reassignment ELI LILLY AND COMPANY Request for Assignment Assignors: BIODEL INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2013249495A 2012-04-16 2013-04-16 Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain Active AU2013249495B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261624844P 2012-04-16 2012-04-16
US61/624,844 2012-04-16
US201261704066P 2012-09-21 2012-09-21
US61/704,066 2012-09-21
US13/826,806 US9381247B2 (en) 2012-04-16 2013-03-14 Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US13/826,806 2013-03-14
PCT/US2013/036742 WO2013158618A1 (en) 2012-04-16 2013-04-16 Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain

Publications (2)

Publication Number Publication Date
AU2013249495A1 AU2013249495A1 (en) 2014-11-06
AU2013249495B2 true AU2013249495B2 (en) 2016-05-12

Family

ID=48326401

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013249495A Active AU2013249495B2 (en) 2012-04-16 2013-04-16 Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain

Country Status (25)

Country Link
US (1) US9381247B2 (https=)
EP (2) EP2838506B1 (https=)
JP (2) JP6422855B2 (https=)
KR (1) KR101966484B1 (https=)
CN (1) CN104394847A (https=)
AU (1) AU2013249495B2 (https=)
CA (1) CA2869883A1 (https=)
CY (1) CY1123825T1 (https=)
DK (1) DK2838506T3 (https=)
ES (1) ES2854874T3 (https=)
HK (2) HK1207577A1 (https=)
HR (1) HRP20210417T1 (https=)
HU (1) HUE053303T2 (https=)
IL (1) IL234987A0 (https=)
IN (1) IN2014DN08417A (https=)
LT (1) LT2838506T (https=)
MX (1) MX2014012245A (https=)
PL (1) PL2838506T3 (https=)
PT (1) PT2838506T (https=)
RS (1) RS61533B1 (https=)
RU (1) RU2014145846A (https=)
SG (1) SG11201406491PA (https=)
SI (1) SI2838506T1 (https=)
WO (1) WO2013158618A1 (https=)
ZA (1) ZA201407410B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104902922B (zh) 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
KR102351111B1 (ko) * 2014-01-13 2022-01-14 써멀린 다이어비티즈, 엘엘씨 초속효성 인슐린 제형 및 약제학적 전달 시스템
WO2015120457A1 (en) * 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
WO2016007935A2 (en) 2014-07-10 2016-01-14 Companion Medical, Inc. Medicine administering system including injection pen and companion device
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
KR20170106373A (ko) * 2015-01-20 2017-09-20 케이스 웨스턴 리저브 유니버시티 선택적 신호전달 특성 및 감소된 유사분열촉진을 갖는 인슐린 유사체
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US10864327B2 (en) 2016-01-29 2020-12-15 Companion Medical, Inc. Automatic medication delivery tracking
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
JP2019529506A (ja) 2016-09-29 2019-10-17 アレコル リミテッド 新規の製剤
GB201707189D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
CN110662551B (zh) 2017-06-01 2023-07-18 伊莱利利公司 速效胰岛素组合物
US11484657B2 (en) 2017-06-09 2022-11-01 Medtronic Minimed, Inc. Intelligent medication delivery systems and methods
US11568975B2 (en) 2017-10-12 2023-01-31 Medtronic Minimed, Inc. Intelligent medication delivery systems and methods for dose recommendation and management
JP7512203B2 (ja) 2017-12-12 2024-07-08 ビッグフット バイオメディカル インコーポレイテッド 治療支援情報及び／又は追跡装置並びに関連する方法及びシステム
US11083852B2 (en) 2017-12-12 2021-08-10 Bigfoot Biomedical, Inc. Insulin injection assistance systems, methods, and devices
US11197964B2 (en) 2017-12-12 2021-12-14 Bigfoot Biomedical, Inc. Pen cap for medication injection pen having temperature sensor
US11116899B2 (en) 2017-12-12 2021-09-14 Bigfoot Biomedical, Inc. User interface for diabetes management systems and devices
US10987464B2 (en) 2017-12-12 2021-04-27 Bigfoot Biomedical, Inc. Pen cap for insulin injection pens and associated methods and systems
US11464459B2 (en) 2017-12-12 2022-10-11 Bigfoot Biomedical, Inc. User interface for diabetes management systems including flash glucose monitor
US11077243B2 (en) 2017-12-12 2021-08-03 Bigfoot Biomedical, Inc. Devices, systems, and methods for estimating active medication from injections
US12357562B2 (en) 2018-04-04 2025-07-15 Arecor Limited Injection pen system for the delivery of an insulin compound
US11664107B2 (en) 2018-05-08 2023-05-30 Medtronic Minimed, Inc. Intelligent medication delivery systems and methods using a prescription-regulated software application
US10898653B2 (en) 2018-05-08 2021-01-26 Companion Medical, Inc. Intelligent medication delivery systems and methods for dose setting and dispensing monitoring
USD893020S1 (en) 2018-05-11 2020-08-11 Companion Medical, Inc. Injection pen
USD892819S1 (en) 2018-06-20 2020-08-11 Companion Medical, Inc. Display screen with graphical user interface
US11587663B2 (en) 2018-06-20 2023-02-21 Medtronic Minimed, Inc. Intelligent medication delivery systems and methods for medicine dose calculation and reporting
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
US12205699B1 (en) 2018-10-30 2025-01-21 Bigfoot Biomedical, Inc. Method of pairing therapy devices using shared secrets, and related systems, methods and devices
US11948671B2 (en) 2019-04-11 2024-04-02 Medtronic Minimed, Inc. Intelligent accessories for medicine dispensing device
CN116847869A (zh) * 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物
US11701473B2 (en) 2021-06-23 2023-07-18 Medtronic Minimed, Inc. Reusable injection pens

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
US5070186A (en) * 1986-10-20 1991-12-03 Novo Industri A/S Magnesium containing insulin solution
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
US7279457B2 (en) * 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20090280532A1 (en) * 1996-08-30 2009-11-12 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US20090304665A1 (en) * 2008-04-28 2009-12-10 Frost Gregory I Super fast-acting insulin compositions
US20100151435A1 (en) * 2007-02-17 2010-06-17 President And Fellows Of Harvard College Compositions and methods for tissue preservation
WO2012006283A1 (en) * 2010-07-07 2012-01-12 Biodel Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK503386D0 (da) * 1986-10-20 1986-10-20 Novo Industri As Peptidpraeparater
US20080096800A1 (en) 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080085298A1 (en) 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) * 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
US5070186A (en) * 1986-10-20 1991-12-03 Novo Industri A/S Magnesium containing insulin solution
US20090280532A1 (en) * 1996-08-30 2009-11-12 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
US7279457B2 (en) * 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20100151435A1 (en) * 2007-02-17 2010-06-17 President And Fellows Of Harvard College Compositions and methods for tissue preservation
US20090304665A1 (en) * 2008-04-28 2009-12-10 Frost Gregory I Super fast-acting insulin compositions
WO2012006283A1 (en) * 2010-07-07 2012-01-12 Biodel Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHIN, YH et al (2011) Korean J Anesthesiol 60: 329-333 *

Also Published As

Publication number Publication date
ES2854874T3 (es) 2021-09-23
US9381247B2 (en) 2016-07-05
SG11201406491PA (en) 2014-11-27
EP2838506A1 (en) 2015-02-25
CY1123825T1 (el) 2022-05-27
EP3827813A1 (en) 2021-06-02
LT2838506T (lt) 2021-03-25
HUE053303T2 (hu) 2021-06-28
EP2838506B1 (en) 2021-01-06
KR101966484B1 (ko) 2019-04-05
ZA201407410B (en) 2015-06-24
JP2015512952A (ja) 2015-04-30
HRP20210417T1 (hr) 2021-04-30
CA2869883A1 (en) 2013-10-24
SI2838506T1 (sl) 2021-02-26
WO2013158618A1 (en) 2013-10-24
CN104394847A (zh) 2015-03-04
HK1203371A1 (en) 2015-10-30
MX2014012245A (es) 2015-06-05
RS61533B1 (sr) 2021-04-29
DK2838506T3 (da) 2021-01-18
KR20140146209A (ko) 2014-12-24
IN2014DN08417A (https=) 2015-05-08
PT2838506T (pt) 2021-02-23
JP2019023223A (ja) 2019-02-14
HK1207577A1 (en) 2016-02-05
US20140113856A1 (en) 2014-04-24
IL234987A0 (en) 2014-12-31
RU2014145846A (ru) 2016-06-10
PL2838506T3 (pl) 2021-06-28
JP6422855B2 (ja) 2018-11-14

Similar Documents

Publication Publication Date Title
AU2013249495B2 (en) Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
AU2013249495A1 (en) Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US8933023B2 (en) Rapid acting injectable insulin compositions
US20150273022A1 (en) Stabilized ultra-rapid-acting insulin formulations
AU2010221397B2 (en) Insulin formulations for rapid uptake
US20120178675A1 (en) Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin
US8084420B2 (en) Rapid acting and long acting insulin combination formulations
WO2013177565A1 (en) Insulin-pramlintide compositions and methods for making and using them
US9399065B2 (en) Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
HK1150793A (en) Rapid acting injectable insulin compositions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ELI LILLY AND COMPANY

Free format text: FORMER OWNER(S): BIODEL INC.